Gamida Cell Ltd. - Ordinary Shares (NQ:GMDA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gamida Cell Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference

May 17, 2022

From Gamida Cell Ltd.

Via Business Wire

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients ↗

April 27, 2022

Via Benzinga

Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings ↗

April 26, 2022

Via Benzinga

Gamida Cell: Q4 Earnings Insights ↗

March 15, 2022

Gamida Cell (NASDAQ:GMDA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Gamida Cell: Q1 Earnings Insights ↗

May 10, 2022

Gamida Cell (NASDAQ:GMDA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Gamida Cell reported in-line EPS of...

Via Benzinga

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

May 10, 2022

From Gamida Cell Ltd.

Via Business Wire

Earnings Preview: Gamida Cell ↗

May 09, 2022

Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Gamida Cell will...

Via Benzinga

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

May 05, 2022

From Gamida Cell Ltd.

Via Business Wire

Cell Therapy-Focused Gamida Plans To Cut 10% Of Staff ↗

January 31, 2022

Gamida Cell Ltd (NASDAQ: GMDA) will terminat

Via Benzinga

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

May 03, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

April 27, 2022

From Gamida Cell Ltd.

Via Business Wire

The Daily Biotech Pulse - Tuesday, April,26 ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Talk Markets

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

April 26, 2022

From Gamida Cell

Via Business Wire

Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

April 25, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

April 25, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

April 07, 2022

From Gamida Cell Ltd.

Via Business Wire

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

March 15, 2022

From Gamida Cell Ltd.

Via Business Wire

Earnings Scheduled For March 15, 2022 ↗

March 15, 2022

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi...

Via Benzinga

Preview: Gamida Cell's Earnings ↗

March 14, 2022

Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

Merck (MRK) Outperforms Industry, What's In Store For 2022? ↗

March 07, 2022

Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.

Via Talk Markets

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Gamida Cell Shares Surge On Rolling Omidubicel Marketing Application In US ↗

February 09, 2022

Gamida Cell Ltd (NASDAQ: GMDA) has initiated the Biologics License Application (BLA)

Via Benzinga

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

February 09, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

January 31, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Provides Key Program Updates and 2022 Financial Guidance

January 31, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Ltd. (NASDAQ:GMDA) Investor Alert: Investigation over Potential Wrongdoing ↗

January 27, 2022

San Diego, CA -- (SBWIRE) -- 01/27/2022 -- Certain directors of Gamida Cell Ltd are under investigation over potential breaches of fiduciary duties.

Via SBWire

48 Biggest Movers From Yesterday ↗

January 21, 2022

Gainers Aptorum Group Limited (NYSE: APM) shares jumped 38.5% to close at $1.69 on Thursday after the company announced it received FDA Orphan Drug designation for...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.